secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clearside Biomedical, Inc. (CLSDQ)
CIK:        0001539029
Form:       8-K
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0000950170-22-015746
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clearside reports Q2 loss of $7.8M, secures $65M non-dilutive financing, OASIS data due Nov
--------------------------------------------------------------------------------

- Net loss $7.8M ($0.13/shr) vs $6.1M ($0.11/shr) in Q2 2021; license revenue $384K down from $780K.
- Cash $29.0M at June 30; initial $32.5M royalty payment from HealthCare Royalty extends runway into 2024.
- CLS-AX OASIS Phase 1/2a top-line data for all four cohorts expected November 2022.
- Non-dilutive financing up to $65M: $32.5M initial, $12.5M escrow, $20M milestone upon XIPERE sales targets.
- Appointed Susan L. Coultas, Ph.D., as Chief Clinical Officer; XIPERE J-code effective July 1, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1539029/000095017022015746/0000950170-22-015746-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1539029/000095017022015746/clsd-20220809.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-015746

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer